Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica

Summary

The study intends to explore the efficacy and safety of Ivarmacitinib in therapy for polymyalgia rheumatica through a multicenter, randomized, double-blind, placebo-controlled study, and to explore the effectiveness of Ivarmacitinib as an oral glucocorticoid-sparing alternative in the treatment of polymyalgia rheumatica.

Conditions

• Polymyalgia Rheumatics (PMR)

Interventions

DRUG

Ivarmacitinib tablet

Targets JAK kinases to block signal transduction of the JAK-STAT pathway

DRUG

placebo for lvarmacitinib

Treatment using blank placebo

Sponsors & Collaborators

• First Affiliated Hospital of Ningbo University

  collaborator NETWORK

• Jinhua Central Hospital

  collaborator OTHER

• First People's Hospital of Hangzhou

  collaborator OTHER

• First Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• Huzhou Central Hospital

  collaborator OTHER

• Ningbo Medical Center Lihuili Hospital

  collaborator OTHER_GOV

• The Second Affiliated Hospital of Jiaxing University

  collaborator OTHER

• Affiliated Hospital of Jiaxing University

  collaborator OTHER

• Changxing People's Hospital

  collaborator OTHER

• Shanghai Zhongshan Hospital

  collaborator OTHER

• Ruijin Hospital

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• The First Affiliated Hospital of Nanchang University

  collaborator OTHER

• RenJi Hospital

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

50 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-01-20

Primary Completion

2027-12-30

Completion

2028-11-30